We report here on a case of 51-year-old woman with metastatic small cell carcinoma of the breast that came from her cancer of the uterine cervix. She underwent radical hysterectomy with bilateral salpingo-oophorectomy due to small cell carcinoma of the uterine cervix, and adjuvant radiotherapy was administered to the pelvis. Breast metastasis with a palpable mass then occurred 3 months after the primary surgery. Simple mastectomy and adjuvant chemotherapy were performed. She initially showed a good response to the therapy, yet she ultimately died of multiple metastases with a fulminating disease course. This is an extremely rare case, and only 1 similar case has been reported earlier, so we report on this case along with a review of the relevant literature.
Introduction
Although primary breast cancer is the most common female cancer in Korea and western countries [1] [2] [3] , breast metastases from extramammary malignancies are uncommon, constituting only about 2% of all breast malignancies [4] . Any malignancy may metastasize to the breast. Lymphoma, melanoma, rhabdomyosarcoma, lung, and ovarian carcinomas are the most common extramammary sources [5] .
Extrapulmonary small cell carcinoma (SCC) is an uncommon malignancy that shares many of the clinical and pathological characteristics of pulmonary SCC, and is a biologically aggressive tumor with a high rate of metastasis [6] [7] [8] [9] [10] . Primary SCC of the uterine cervix is a rare neuroendocrine tumor constituting up to 6% of all uterine cervical cancers with about 200 reported cases [11, 12] . Metastatic SCC of the breast from the uterine cervix is extremely rare, and only 1 case has been reported [13] .
Case Report
A 51-year-old postmenopausal woman presented with a month of vaginal bleeding. An MRI revealed a 9.0-cm diameter, well-defined bulging mass at the posterior lip of the uterine cervix with upper vaginal involvement, but there was no evidence of distant metastases. These findings were compatible with uterine cervical cancer. First, a radical hysterectomy and a bilateral salpingo-oophorectomy were performed. The tumor size was 6.0 × 6.0 × 3.0 cm involving the full thickness of the cervix. There was no parametrial or uterine invasion, but lymphovascular invasion was present and 7 out of 34 dissected lymph nodes were involved. Thus, the FIGO stage was IIb. Immunohistochemical staining showed tumor cells positive for synaptophysin and chromogranin (Fig. 1a, b) . These findings were consistent with SCC of the uterine cervix. Adjuvant radiation therapy (4,860 cGy) to the pelvic region was performed.
Three months after the primary surgery, the patient was referred to the department of breast surgery with a palpable painless lump in the right breast. A 3.0-cm sized, wellcircumscribed, round, movable, non-tender, and hard mass was palpated in the upper outer quadrant of the right breast with no associated axillary lymphadenopathy. Mammograms showed a 2.5-cm sized, well-defined, round, and lobulated mass in the upper outer quadrant of the right breast, suggesting a well-circumscribed breast cancer (Fig. 2a) . Ultrasound examination demonstrated 3.0 × 3.0 × 3.0 cm and 1.7 × 1.0 × 2.0 cm sized heterogeneous, hypoechoic, irregular-margined masses in the right breast (Fig. 2b) . These masses showed prominent blood flow on a color Doppler image, consistent with breast cancer. Fine needle aspiration cytology was performed. Tumor cells with diffuse and strongly positive immunohistochemical staining for synaptophysin and chromogranin, respectively, were observed. These results supported the diagnosis of SCC. A right simple mastectomy without axillary lymph node dissection was performed. Surgical pathology revealed 4.0 × 4.0 × 3.8 cm and 2.5 × 2.5 × 2.3 cm sized carcinomas without any intraductal component. The tumors had no involvement of the nipple or skin, but lymphovascular invasion was seen. The surgical resection margins were clear. The findings of multiple lesions, the absence of in situ carcinoma, well-demarcated tumors, and a history of SCC were compatible with the diagnosis of metastatic SCC (Fig. 2c) . Immunohistochemical staining showed tumor cells strongly positive for synaptophysin and chromogranin (Fig. 2d) and negative for CK-20 and CK-7. These findings supported the diagnosis.
Two weeks after surgery, 3.0-and 1.0-cm sized masses were palpated in the lateral portion of the right chest wall. The patient received adjuvant chemotherapy with an EP regimen (etoposide and cisplatin). After the first cycle of chemotherapy, the masses completely disappeared and could not be palpated. The masses appeared to be responsive to chemotherapy, and 6 cycles with the EP regimen were completed. However, new masses were palpated in the right chest wall, and a bone scan showed bone metastasis in the right proximal humerus. A second phase of chemotherapy was performed with paclitaxel and carboplatin. During the chemotherapy, the patient presented with lower abdominal pain and hematochezia due to proximal ileal bleeding from a bulky tumor in the abdominal cavity. The patient died of disseminated intravascular coagulopathy.
Discussion
Extrapulmonary SCC is an uncommon malignancy that is reported as a biologically aggressive tumor with a poor prognosis [6] [7] [8] [9] [10] . Primary SCC of the breast is one of the least common types of breast cancer, and fewer than 25 cases have been reported in the literature. Immunohistochemical analysis of primary breast SCC demonstrated immunoreactivity for neuron-specific enolase (NSE), E-cadherin, thyroid transcription factor-1 (TTF-1), bcl-2, synaptophysin, and chromogranin. Primary SCC of the breast is characteristically CK-7 positive and CK-20 negative, whereas pulmonary SCC is negative for both [6, 9, 10] . It is difficult to distinguish metastatic breast carcinoma from primary breast carcinoma. However, some histological features are useful for the diagnosis of metastasis, such as atypical histological features for a primary breast carcinoma, a well-circumscribed tumor with multiple satellite foci, absence of an in situ intraductal component, and the presence of many lymphatic emboli [14] . Our findings, including multiple lesions, absence of in situ carcinoma, welldemarcated tumors, a history of SCC, strong positive reactions for synaptophysin and chromogranin, and negative reactions for CK-20 and CK-7 confirmed the diagnosis of metastatic SCC of the breast from the uterine cervix.
There is no standard therapy for extrapulmonary and metastatic SCC due to its rarity. However, it seems acceptable that the disease should be treated in the same manner as pulmonary SCC. The commonly used chemotherapeutic agents are etoposide and cisplatin. Despite aggressive multidisciplinary treatments, this case showed a rapid fatal clinical course. Metastatic SCC of the breast from the uterine cervix is extremely rare, and only 1 previous case has been reported [13] .
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